VACC Vaccitech plc

Biotech Analyst Ratings

Latest News

1. 11 May 2022 Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments

   OXFORD, United Kingdom, May 11, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of the Company's recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer.
   

   "We've already made solid progress across the Company this year and are excited to share our plans to advance our recently acquired SNAPvax platform into the clinic in multiple disease indications including HPV cancer and celiac disease," said Bill Enright, Vaccitech's CEO. "These are devastating…

   View Full Article
2. 06 April 2022 Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®

   OXFORD, United Kingdom, April 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that it has been notified of the commencement of royalty payments relating to commercial sales of Vaxzevria®. Vaccitech's share of milestone and royalty payments, arising from AstraZeneca's commercial sales of Vaxzevria® during the fourth quarter of 2021, amounts to approximately $15 million.
   

   Vaxzevria® is a SARS-CoV2 vaccine that was developed using Vaccitech's and Oxford University's ChAdOx technology. In 2020, Vaccitech assigned its rights in Vaxzevria® to Oxford University Innovation (OUI) to facilitate the license…

   View Full Article
3. 25 March 2022 Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments

   OXFORD, United Kingdom, March 25, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) today announced its financial results for the full year ended December 31, 2021 and provided an overview of the Company's recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer.
   

   "2021 was a pivotal year for Vaccitech during which we achieved a number of strategic, operational, and financial objectives, advanced multiple immunotherapeutic and prophylactic candidates in clinical development and strengthened and expanded our T cell activating discovery engine platform via…

   View Full Article
4. 07 March 2022 Vaccitech to Present at the Barclays Global Healthcare Conference 2022

   OXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Barclays Global Healthcare Conference at 2:05 p.m. EDT on Tuesday, March 15, 2022, in Miami.
   

   A live webcast of the presentation can be accessed through the Events section of the Vaccitech website. Following the live webcast, a replay will be available at the same location.

   About Vaccitech plc
   Vaccitech ("the Company") is a clinical-stage biopharmaceutical company engaged…

   View Full Article
5. 18 January 2022 Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

   OXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (NASDAQ:VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600, in patients with the most common type of lung cancer.
   

   The phase I/IIa trial is expected to enroll approximately 86 people who have been newly diagnosed with non-small cell lung cancer (NSCLC) and will be testing the safety and initial efficacy of VTP-600 in these patients. VTP-600 will be given in combination with the current first line treatment for NSCLC.

   If further clinical trials are successful, VTP-600 could prove to be a powerful new treatment for a group of patients…

   View Full Article